> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Granules India Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/granules-india-moat/
- Published: 2026-08-16T16:25:33.000Z
- Updated: 2026-08-22T05:14:11.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Granules India Ltd.

A first-pass moat teardown of Granules India Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**16 Aug 2026 First-pass · \~3 min

5.78 / 10

NARROW → WIDEProcess/Data-led

First-pass narrow-to-wide read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Granules India Ltd. scores **5.78** on MoatSCORE 6.0 — a narrow-to-wide moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D3Cost Advantage7

M · Mechanism✓ Verified verbatim

“Renowned for our efficient and cost-effective manufacturing operations, we specialize in delivering high-quality APIs.”

**Granules India Ltd.** · Annual Report · p.9

D4Price Discretion6

M · Mechanism✓ Verified verbatim

“The US generic pharma industry has been grappling with pricing pressure, supply chain issues, and cost inflation, severely impacting the margins of the players.”

**Granules India Ltd.** · Annual Report · p.54

D5Intangible Assets6

M · Mechanism✓ Verified verbatim

“Dr. Prasad with his passion for innovation undertook research in process chemistry and filed 33 patents, out of which 5 patents were granted so far.”

**Granules India Ltd.** · Annual Report · p.17

D2Switching Costs5.2

M · Mechanism✓ Verified verbatim

“The warning letter does not affect the supply of approved commercial products. However, it may temporarily impact the FDA's review of pending product submissions from this facility until the matter is resolved.”

**Granules India Ltd.** · Earnings Call · p.3

D1Network Effects4.8

M · Mechanism✓ Verified verbatim

“Global commercial reach over 60 countries and with leadership position in select generic drugs”

**Granules India Ltd.** · Annual Report · p.12

D6Efficient Scale4.8

M · Mechanism✓ Verified verbatim

“Since setting up a PFI manufacturing facility comprises more than 80% of the total investments, the customers can reduce their expenditure by a great extent.”

**Granules India Ltd.** · Annual Report · p.26

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?7.0

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?6.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow-to-wide read. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).